B-vitamin therapy for diabetic nephropathy: Reply

JAMA

Volumn 304, Issue 6, 2010, Pages 636-637

  Spence, J David ^a   House, Andrew A ^b   Eliasziw, Misha ^c  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; PLACEBO; PYRIDOXINE; VITAMIN B GROUP; VITAMIN B COMPLEX;

CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; NOTE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY;

DIABETIC NEPHROPATHIES; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; VITAMIN B 12; VITAMIN B 6; VITAMIN B COMPLEX;

EID: 77955350748     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1106     Document Type: Letter

References (4)

1. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
2. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
3. Schwartz MM, Lewis EJ, Leonard-Martin T, Lewis JB, Batlle D; The Collaborative Study Group. Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. Nephrol Dial Transplant. 1998;13(10):2547-2552.
4. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative Workgroup. Acute renal failure: definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204-R212.